BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $276,316 | -28.5% | 7,324 | -13.7% | 0.05% | -26.9% |
| Q2 2023 | $386,523 | +8.8% | 8,484 | -3.1% | 0.07% | +4.7% |
| Q1 2023 | $355,257 | -24.1% | 8,759 | -4.6% | 0.06% | -26.4% |
| Q4 2022 | $468,079 | -11.2% | 9,184 | -6.1% | 0.09% | -16.3% |
| Q3 2022 | $527,000 | -33.3% | 9,784 | -20.4% | 0.10% | -30.2% |
| Q2 2022 | $790,000 | -33.2% | 12,299 | -19.3% | 0.15% | -22.4% |
| Q1 2022 | $1,182,000 | -9.3% | 15,244 | -0.7% | 0.19% | -11.5% |
| Q4 2021 | $1,303,000 | -7.9% | 15,344 | -12.7% | 0.22% | -10.3% |
| Q3 2021 | $1,414,000 | -4.1% | 17,580 | -4.0% | 0.24% | -6.6% |
| Q2 2021 | $1,474,000 | -9.2% | 18,313 | -4.9% | 0.26% | -16.2% |
| Q1 2021 | $1,623,000 | -3.5% | 19,248 | -8.1% | 0.31% | -12.2% |
| Q4 2020 | $1,681,000 | -10.8% | 20,953 | -10.6% | 0.35% | -17.9% |
| Q3 2020 | $1,885,000 | -0.4% | 23,440 | +6.6% | 0.43% | -8.7% |
| Q2 2020 | $1,893,000 | +15.3% | 21,987 | +8.7% | 0.47% | -5.2% |
| Q1 2020 | $1,642,000 | -3.5% | 20,228 | -0.6% | 0.50% | +22.8% |
| Q4 2019 | $1,702,000 | -5.1% | 20,353 | -0.7% | 0.40% | -12.9% |
| Q3 2019 | $1,793,000 | +6.3% | 20,491 | -0.5% | 0.46% | +1.5% |
| Q2 2019 | $1,686,000 | +1.4% | 20,590 | +0.7% | 0.46% | -2.6% |
| Q1 2019 | $1,663,000 | +25.6% | 20,450 | +1.6% | 0.47% | +8.6% |
| Q4 2018 | $1,324,000 | -12.0% | 20,125 | +3.1% | 0.43% | +0.2% |
| Q3 2018 | $1,504,000 | +3.7% | 19,515 | -0.7% | 0.43% | -3.6% |
| Q2 2018 | $1,451,000 | +11.4% | 19,650 | -1.9% | 0.45% | +7.7% |
| Q1 2018 | $1,302,000 | +2.0% | 20,025 | +1.3% | 0.42% | +2.7% |
| Q4 2017 | $1,277,000 | +0.9% | 19,759 | -2.0% | 0.40% | -4.5% |
| Q3 2017 | $1,265,000 | +3.3% | 20,163 | -0.2% | 0.42% | -1.9% |
| Q2 2017 | $1,224,000 | +16.2% | 20,213 | -0.5% | 0.43% | +9.4% |
| Q1 2017 | $1,053,000 | +14.2% | 20,313 | -2.3% | 0.39% | +10.1% |
| Q4 2016 | $922,000 | -7.6% | 20,788 | -0.8% | 0.36% | -17.1% |
| Q3 2016 | $998,000 | +3.0% | 20,962 | -2.1% | 0.43% | 0.0% |
| Q2 2016 | $969,000 | +8.3% | 21,422 | -1.7% | 0.43% | -3.6% |
| Q1 2016 | $895,000 | +6.7% | 21,787 | -0.9% | 0.45% | +3.7% |
| Q4 2015 | $839,000 | +17.8% | 21,987 | +1.4% | 0.43% | +11.1% |
| Q3 2015 | $712,000 | -53.1% | 21,690 | -0.2% | 0.39% | -49.7% |
| Q2 2015 | $1,519,000 | +2.1% | 21,725 | 0.0% | 0.77% | +1.8% |
| Q1 2015 | $1,488,000 | +12.0% | 21,725 | +19.9% | 0.76% | +8.9% |
| Q4 2014 | $1,328,000 | +9.9% | 18,125 | +7.7% | 0.70% | +4.0% |
| Q3 2014 | $1,208,000 | +7.5% | 16,825 | +11.8% | 0.67% | +3.6% |
| Q2 2014 | $1,124,000 | +1.2% | 15,050 | -0.3% | 0.65% | -4.4% |
| Q1 2014 | $1,111,000 | +21.0% | 15,095 | +14.4% | 0.68% | +17.3% |
| Q4 2013 | $918,000 | – | 13,195 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |